ARTA
CLDX icon

A.R.T. Advisors’s Celldex Therapeutics CLDX Stock Holding History

A.R.T. Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-21,541
Closed -$48K – 231
2019
Q4 		$48K Buy
21,541
+1,800
+9% +$4.18K ﹤0.01% 1250
2019
Q3 		$42K Sell
19,741
-33,000
-63% -$76.4K ﹤0.01% 1328
2019
Q2 		$141K Buy
52,741
+21,741
+70% +$73.8K 0.01% 1154
2019
Q1 		$153K Buy
+31,000
New +$163K 0.01% 1115
2018
Q2 		– Sell
-7,477
Closed -$261K – 1464
2018
Q1 		$261K Buy
7,477
+2,187
+41% +$84.7K 0.01% 1181
2017
Q4 		$225K Sell
5,290
-382
-7% -$16.4K 0.01% 1123
2017
Q3 		$243K Buy
+5,672
New +$213K 0.01% 1080
2017
Q2 		– Sell
-7,160
Closed -$387K – 1447
2017
Q1 		$387K Sell
7,160
-3,713
-34% -$193K 0.02% 901
2016
Q4 		$577K Buy
10,873
+9,826
+938% +$559K 0.03% 685
2016
Q3 		$63K Sell
1,047
-31,207
-97% -$1.94M 0.02% 585
2016
Q2 		$2.12M Sell
32,254
-28,534
-47% -$1.81M 0.11% 295
2016
Q1 		$3.45M Buy
+60,788
New +$6.84M 0.15% 183
2015
Q2 		– Sell
-597
Closed -$249K – 1499
2015
Q1 		$249K Buy
+597
New +$214K 0.01% 1166
2014
Q2 		– Sell
-5,729
Closed -$1.52M – 1324
2014
Q1 		$1.52M Buy
5,729
+3,580
+167% +$1.37M 0.08% 345
2013
Q4 		$780K Buy
+2,149
New +$828K 0.04% 591
2013
Q3 		– Sell
-4,060
Closed -$950K – 1324
2013
Q2 		$950K Buy
+4,060
New +$799K 0.03% 650

Other funds holding CLDX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

A.R.T. Advisors's CLDX Position: Q1 2020 in Review

A.R.T. Advisors sold out of Celldex Therapeutics (CLDX) in Q1 2020, closing a stake of 21,541 shares — an estimated $48K sold.

A.R.T. Advisors first reported a position in CLDX in Q2 2013 and held it in 16 quarters. The position peaked at $3.45M in Q1 2016. 45 funds tracked by Wall St. Rank hold CLDX as of Q1 2020.

  • A.R.T. Advisors reported no remaining Celldex Therapeutics position as of Q1 2020 after selling out during the quarter.
  • A.R.T. Advisors sold 21,541 Celldex Therapeutics shares in Q1 2020, an estimated $48K.
  • A.R.T. Advisors first reported a position in Celldex Therapeutics in Q2 2013 and held it in 16 quarters.
  • A.R.T. Advisors's Celldex Therapeutics position peaked at $3.45M in Q1 2016.
  • 45 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2020.

Based on A.R.T. Advisors's 13F filing for Q1 2020, filed 15 May 2020.